Table 1.

Patient characteristics

Variables	Hyperthyroidism group			Control groups			F	P
	TNGT	TIGR	TDM	NGT	IGR	T2DM
n (male/female)	32 (11/21)	35 (18/17)	34 (18/16)	33 (22/11)	28 (19/9)	35 (22/13)
Age (years)	41.48± 11.71‡,¶	48.00± 12.27	54.71± 12.71*,§	45.26± 15.43‡,¶	48.29± 12.98	54.31± 12.40*,§	4.093	0.002
BMI (kg/m2)	22.21± 4.45§,||	21.67± 4.83§,||	22.79± 5.45§,||	26.80± 4.97*,†,‡,¶	26.32± 5.05*,†,‡	24.31± 3.98§	9.416	0.000
Diabetes duration (months)	0¶	0¶	0¶	0¶	0.27 (0.10± 3.25)¶	38.00 (15.00± 61.00)*,†,‡,§,||	15.555	0.000
T3 (nmol/L)	4.09± 1.88§,||,¶	4.04± 1.74§,||,¶	3.08± 1.73||,¶	2.27± 1.60*,†	1.93± 1.34*,†,‡	1.73± 1.31*,†,‡	11.278	0.000
T4 (nmol/L)	172.90± 1.94§,||,¶	218.59± 1.51§,||,¶	156.27± 1.61§,||,¶	100.08± 1.85*,†,‡	111.81± 1.26*,†,‡	114.33± 1.24*,†,‡	9.167	0.000
FT3 (pmol/L)	12.42± 2.74§,||,¶	13.21± 1.97§,||,¶	9.33± 2.37§,||,¶	5.30± 1.63*,†,‡	5.14± 1.53*,†,‡	4.43± 1.12*,†,‡	12.848	0.000
FT4 (pmol/L)	26.25± 3.16§,||,¶	33.82± 1.89§,||,¶	23.76± 2.78§,||,¶	11.34± 1.21*,†,‡	12.01± 1.39*,†,‡	12.17± 1.17*,†,‡	11.028	0.000
TSH (mU/L)	0.02 (0.01, 0.07)§,||,¶	0.01 (0.01, 004)§,||,¶	0.06 (0.01, 0.24)§,||,¶	1.97 (1.01, 2.63)*,†,‡	1.44 (0.81, 2.51)*,†,‡	1.79 (0.94, 2.48)*,†,‡	32.067	0.000

Data are expressed as mean ± standard deviation or median (Q1, Q3). *P<0.05 by one-way ANOVA (vs. TNGT); ^†P<0.05 by one-way ANOVA (vs. TIGR); ^‡P<0.05 by one-way ANOVA (vs. TDM); ^§P<0.05 by one-way ANOVA (vs. NGT); ^||P<0.05 by one-way ANOVA (vs. IGR); ^¶P<0.05 by one-way ANOVA (vs. T2DM). TNGT: Hyperthyroidism with normal glucose tolerance; TIGR: Hyperthyroidism with impaired glucose regulation; TDM: Hyperthyroidism with diabetes mellitus; NGT: Normal glucose tolerance control group; IGR: Impaired glucose regulation control group; T2DM: Type 2 diabetes mellitus control group; BMI: Body mass index; T3: Triiodothyronine; T4: Thyroxine; FT3: Free T3; FT4: Free T4; TSH: Thyroid-stimulating hormone; ANOVA: Analysis of variance.